Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The objectives of this Phase I study are to determine the maximum tolerable dose (MTD) and to
evaluate pharmacokinetics (PK), safety/ tolerability and preliminary efficacy of OB318 in
patients with advanced solid malignancies.